CD79A and infection: While analysis from RV144 trial vaccinees indicated that serum IgA positively correlated with infection risk, Sholukh and colleagues found that the combination of dIgA and IgG (targeting the same HGN194 (a neutralizing epitope in env)), applied intrarectally, led to 100% protection from intrarectal challenge [14].